Genrix Bio
- Company typePublic
- Founded2015
- HeadquartersBanan, China
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genrix Bio does
Genrix Bio (Chongqing Genrix Biopharmaceutical Co., Ltd., Stock Code: 688443) is a publicly listed Chinese biopharmaceutical company founded in 2015, focused on antibody drug discovery and development. The company is headquartered in Chongqing (Banan District) and operates additional R&D centers in Beijing and Shanghai, employing 51–100 people. It pursues first-in-class and best-in-class antibody therapeutics across three therapeutic areas: autoimmune diseases (lead candidates GR1501/Xeligekimab, GR1802/Telikibart, GR1603, GR2002, GR2301, GR2303), infectious diseases (GR1801/Silevimig, GR2001/Vecantoxatug, GR2102, GR2302), and oncology (GR1803/Velinotamig, a BCMA×CD3 bispecific, plus GR1901, WM202, GR2304).
The company's underlying technology is an integrated industry chain platform spanning antibody molecular discovery, process development, quality research, clinical trials, and large-scale commercialization. The portfolio covers monoclonal antibodies, bispecific antibodies, and polyspecific antibodies. Genrix Bio is listed on the Shanghai Stock Exchange STAR Market, providing public capital access and regulatory visibility. Its end customers are patients with autoimmune, infectious, and oncologic diseases, accessed through traditional Chinese pharmaceutical distribution channels for commercialization. Pricing details are not publicly disclosed, consistent with a pipeline-stage biopharmaceutical firm.
Genrix Bio firmographics
Firmographics- Name
- Genrix Bio
- Legal name
- Chongqing Genrix Biopharmaceutical Co., Ltd.
- Website
- https://genrixbio.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Genrix Bio industry classification
Industry- Product category
- Biopharmaceutical Antibody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Bispecific & Multispecific Antibodies (HLAAAAAF), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Genrix Bio is headquartered
LocationHeadquarters
- HQ city
- Banan
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
Genrix Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Distribution channels1 record
Marketing channels1 record
Genrix Bio product offering
Product offeringCore offering
Genrix Bio discovers and develops antibody drugs — including monoclonal, bispecific, and polyspecific antibodies — targeting autoimmune diseases, infectious diseases, and oncology. Its integrated industry-chain platform spans antibody molecular discovery, process development, quality research, clinical trials, and large-scale commercialization, with R&D centers in Chongqing, Beijing, and Shanghai and a pipeline of more than a dozen named candidates.
Product overview
Genrix Bio (Chongqing Genrix Biopharmaceutical Co., Ltd., Stock Code: 688443) is a biopharmaceutical company focused on antibody drug discovery and development. The company operates an integrated industry chain platform with R&D centers in Beijing, Shanghai, and Chongqing, spanning from antibody molecular discovery through clinical trials to large-scale commercialization. Their portfolio includes monoclonal antibodies, bispecific antibodies, and polyspecific antibodies across three therapeutic areas: autoimmune diseases (GR1501/Xeligekimab, GR1802/Telikibart, GR1603, GR2002, GR2301, GR2303), infectious diseases (GR1801/Silevimig, GR2001/Vecantoxatug, GR2102, GR2302), and oncology (GR1803/Velinotamig, GR1901, WM202, GR2304).
Differentiator
Problem solved
Functional benefit
Products and services
- GR1501 (Xeligekimab) Monoclonal antibody therapy in development for the treatment of autoimmune diseases, intended for patients with significant unmet clinical need.
- GR1802 (Telikibart) Monoclonal antibody therapy in development for the treatment of autoimmune diseases.
- GR1603 Monoclonal antibody therapy in development for autoimmune diseases.
- GR2002 Monoclonal antibody therapy in development for autoimmune diseases.
- GR2301 Monoclonal antibody therapy in development for autoimmune diseases.
- GR2303 Monoclonal antibody therapy in development for autoimmune diseases.
- GR1801 (Silevimig) Monoclonal antibody therapy in development for the treatment of infectious diseases.
- GR2001 (Vecantoxatug) Monoclonal antibody therapy in development for the treatment of infectious diseases.
- GR2102 Monoclonal antibody therapy in development for infectious diseases.
- GR2302 Monoclonal antibody therapy in development for infectious diseases.
- GR1803 (Velinotamig) Bispecific antibody therapy in development for oncology, targeting BCMA and CD3, for cancer patients.
- GR1901 Antibody therapy in development for oncology.
- WM202 Antibody therapy in development for oncology.
- GR2304 Antibody therapy in development for oncology.
- Integrated Industry Chain Platform Antibody drug R&D platform spanning molecular discovery, process development, quality research, clinical trials, and large-scale commercialization, with R&D centers in Beijing, Shanghai, and Chongqing, supporting Genrix Bio's pipeline of monoclonal, bispecific, and polyspecific antibodies.
Companies that use Genrix Bio
Customer profileSegments3 records
Ideal customer profiles1 record
Genrix Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Genrix Bio partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights5 records
Genrix Bio competitors and assessment
Company assessmentDirect peers
- Innovent Biologics: Innovent is a leading Chinese biologics developer with commercialized mAb products and a deep oncology/autoimmune pipeline. Comparable for antibody modality, China-focused commercialization, and integrated discovery-to-commercial capabilities.
- Junshi Biosciences: Junshi Biosciences is a STAR Market-listed Chinese antibody innovator (Stock Code: 688180) with mAb and bispecific programs in oncology and autoimmune diseases. Highly comparable for therapeutic area focus, antibody modality, and STAR Market capital structure.
- Akeso: Akeso is a Hong Kong-listed Chinese biotech focused on bispecific and monoclonal antibody therapeutics in oncology and immunology. Directly comparable for its bispecific antibody platform and pipeline-stage assets serving similar indications.
- RemeGen: RemeGen is a Chinese antibody biotech with approved mAb products and ADC/bispecific pipeline. Comparable for therapeutic focus (autoimmune, oncology) and integrated biologics platform in China.
Broad incumbents
- BeiGene: BeiGene is a large global oncology biotech with significant China operations and antibody capabilities. Comparable for therapeutic area overlap (oncology) and China-based R&D, though substantially larger and more diversified.
- Genmab: Genmab is a Denmark-based antibody specialist with proprietary bispecific platforms (DuoBody, HexaBody) and multiple commercialized products. Comparable for bispecific antibody technology leadership and innovation-driven business model.
- Hansoh Pharmaceutical: Hansoh is a major Chinese pharmaceutical company with a strong biologics pipeline and commercial infrastructure. Comparable for antibody modality focus and China commercialization, though it operates a broader small-molecule + biologics portfolio.
Emerging players
- Cstone Pharmaceuticals: Cstone is a clinical-stage Chinese oncology biotech focused on immuno-oncology biologics including bispecific antibodies. Comparable for emerging-stage antibody pipeline and China-listed status.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Genrix Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genrix Bio leadership team
Management profileNumber of profiles
Genrix Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genrix Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genrix Bio
What does Genrix Bio do?
Genrix Bio discovers and develops antibody drugs — including monoclonal, bispecific, and polyspecific antibodies — targeting autoimmune diseases, infectious diseases, and oncology. Its integrated industry-chain platform spans antibody molecular discovery, process development, quality research, clinical trials, and large-scale commercialization, with R&D centers in Chongqing, Beijing, and Shanghai and a pipeline of more than a dozen named candidates.
Is Genrix Bio a public or private company?
Genrix Bio is a public company. It is classified as public and is currently operating.
When was Genrix Bio founded?
Genrix Bio was founded in 2015. It employs 1 to 10 people.
Where is Genrix Bio based?
Genrix Bio is headquartered in Banan, China, in the Asia region.
Who are Genrix Bio's main competitors?
Direct peers on record are Innovent Biologics, Junshi Biosciences, Akeso and RemeGen. Broad incumbents are BeiGene, Genmab and Hansoh Pharmaceutical. Cstone Pharmaceuticals is listed as an emerging player.
Does Genrix Bio have an API?
No public API is recorded for Genrix Bio.
What industry is Genrix Bio in?
Genrix Bio's product category is Biopharmaceutical Antibody Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 325414 and its SIC code is 2834.